HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI
28.4.2026 15:22:00 CEST | Business Wire | Press release
Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact
AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/

HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning.
HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. The data suggests that AI progress in healthcare is becoming uneven—strong in pockets of innovation, but difficult to extend across the full complexity of care delivery and regulated operations.
“Real value emerges only when technology is thoughtfully embedded into clinicians’ everyday workflows, aligned with how care is actually delivered,” said Alfred Olivares, Managing Partner, Healthcare & Life Sciences at HTEC. “AI must complement clinical expertise—not disrupt it—if it is to deliver meaningful impact.”
AI Widespread, Scale Elusive
AI is now firmly on the strategic agenda across healthcare and life sciences. More than half of organizations (52.2%) report that AI is already embedded across multiple functions, and virtually all leaders consider it a priority.
Despite widespread adoption, scaling AI across clinical, operational, and R&D environments remains difficult—slowed by fragmented systems, capability gaps, and the need to balance innovation with safety, compliance, and trust.
Integration and Execution Alignment are the Biggest Barriers
The research identifies system integration and executive alignment as the primary obstacles to scaling AI in healthcare.
These challenges are amplified by:
- Fragmented clinical and enterprise systems
- Strict regulatory and compliance requirements
- Highly distributed ecosystems involving providers, patients, payors, and regulators
While 85.8% of leaders report strong or full alignment at a strategic level, 42.3% still cite lack of alignment as a barrier, highlighting a critical gap between intent and execution.
In practice, organizations often agree that AI matters, but diverge on how to prioritize use cases, allocate investment, and operationalize it safely at scale.
Edge AI Emerges as a Strategic Priority
Edge AI plays a uniquely strategic role in healthcare and life sciences. Nearly all leaders report familiarity with edge AI, and 97.9% express confidence in their ability to deploy it.
Notably, most organizations are adopting a hybrid edge-to-cloud approach—combining partnerships (61.7%), in-house development (53.6%), and third-party platforms (53.2%) to connect real-time data from devices and care settings with centralized clinical, research, and analytics systems.
This reflects the growing importance of distributed care models, connected medical devices, and the need to process sensitive data closer to the point of care.
Capability Gaps are Slowing Progress and Increasing Costs
Despite strong adoption, nearly all organizations (93.7%) report technical skill gaps that are directly impacting their ability to scale AI. The most critical gaps center around cybersecurity and data privacy, AI/ML expertise, and DevOps and automation. These constraints are already translating into measurable business impact, with 51.5% of organizations reporting higher costs, 41.4% experiencing reduced innovation, and 36.7% facing slower time to market.
Only One in Three Organizations Ready to Scale AI
Despite strong adoption and confidence in emerging technologies like edge AI, only about a third of healthcare organizations believe they can scale AI rapidly.
At the same time, leaders estimate that failing to act on AI and edge opportunities would set them back by 1.65 years on average, underscoring how narrow the competitive window has become.
This creates a clear inflection point: organizations must move beyond experimentation and isolated use cases toward coordinated, enterprise-wide execution.
The Next Phase of Healthcare AI
Healthcare and life sciences have already demonstrated strong momentum in AI adoption. But the next phase will not be defined by how widely AI is used, but how effectively it is operationalized and blended with the current clinician workflows.
The organizations that move ahead will be those that:
- Build governed, reusable data foundations
- Align leadership at both strategic and execution levels
- Invest in workforce enablement alongside technology
- Integrate AI directly into clinical and operational workflows
“The competitive window is narrow, but it is not yet closed,” said Stefan Mrsic, Managing Partner, Healthcare & Life Sciences at HTEC. “The next phase will be defined by the ability to combine innovation with safety, explainability, and human judgment.”
The State of AI in the Healthcare and Life Sciences Industry 2025-2026 is now available for download.
About the Research
The report was commissioned by HTEC and conducted by Censuswide. It includes the insights from 1,529 C-suite leaders across the USA, UK, Germany, Spain, Saudi Arabia, and the UAE, spanning CEOs, CIOs, CTOs, CDOs, CFOs, COOs, CPOs, and CSOs across industries, including financial services, healthcare, automotive, telecommunications, retail, and semiconductors.
About HTEC
HTEC Group Inc. is a global AI-first provider of strategic, software and hardware embedded design and engineering services, specializing in Advanced Technologies, Financial Services, MedTech, Automotive, Telco, and Enterprise Software & Platforms. HTEC has a proven track record of helping Fortune 500 and hyper-growth companies solve complex engineering challenges, drive efficiency, reduce risks, and accelerate time to market. HTEC prides itself on attracting top talent and has strategically chosen the locations of its 20+ excellence centers to enable this.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260428872907/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom